Skip to main content
SpringerLink
Log in

Lipid Formulations of Amphotericin B

Less Toxicity But at What Economic Cost?

  • Leading Article
  • Published:
Drug Safety Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Bodey G, Bueltman B, Duguid W, et al. Fungal infections in cancer patients: an international autopsy survey. Eur J Microbiol Infect Dis 1992; 11: 99–109

    Article  CAS  Google Scholar 

  2. Meunier F. Fungal infections in the compromised host. In: Rubin RH, Young LS, editors. Clinical approach to infection in the compromised host. 2nd ed. New York: Plenum Medical Book Co., 1989: 193–220

    Google Scholar 

  3. Meyers JD. Fungal infections in bone marrow transplant patients. Semin Oncol 1990; 17 Suppl. 6: 10–3

    PubMed  CAS  Google Scholar 

  4. Denning DW. Epidemiology and pathogenesis of systemic fungal infections in the immunocompromised host. J Antimicrob Chemother 1991; 28 Suppl. B: 1–16

    PubMed  Google Scholar 

  5. Tollemar J. Invasive fungal infections — incidence, diagnosis, risk-factors and treatment in bone marrow and liver transplant recipients [dissertation]. Stockholm: Karolinska Institutet, 1991

    Google Scholar 

  6. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990; 12: 308–29

    Article  PubMed  CAS  Google Scholar 

  7. Holleran WM, Wilbur JR, De Gregorio MW. Empiric amphotericin B therapy in patients with acute leukemia. Rev Infect Dis 1985; 7: 618–24

    Article  Google Scholar 

  8. Medoff G, Brajtburg J, Kobayashi GS. Antifungal agents useful in therapy of systemic fungal infections. Ann Rev Pharmacol Toxicol 1983; 2: 303–30

    Google Scholar 

  9. Odds FC. Candida and candidosis. 2nd ed. London: Baillière Tindall, 1988

    Google Scholar 

  10. Dick JD, Metz WG, Sarai R. Incidence of polyene-resistant yeasts recovered from clinical specimens. Antimicrob Chemother 1980; 18: 158–63

    Article  CAS  Google Scholar 

  11. Warnock DW. Amphotericin B: an introduction. J Antimicrob Chemother 1991; 28 Suppl. B: 27–38

    PubMed  CAS  Google Scholar 

  12. Powderly WG, Kobayashi GS, Herzig GP, et al. Amphotericin B-resistant yeast infections in immunocompromised patients. Am J Med 1988; 84: 826–32

    Article  PubMed  CAS  Google Scholar 

  13. Utz JP. Amphotericin B toxicity: introduction. Ann Intern Med 1964; 61: 334

    CAS  Google Scholar 

  14. Maddux MS, Barriere SL. A review of complications of amphotericin B therapy: recommendations for prevention and management. Drug Intell Clin Pharm 1980; 14: 177–88

    Google Scholar 

  15. Medoff G, Kobayashi GA. The polyenes. In: Speller DCE, editor. Antifungal chemotherapy. Chichester: John Wiley and Sons, 1980: 3–34

    Google Scholar 

  16. Barriere SL. Pharmacology and pharmacokinetics of traditional systemic antifungal agents. Pharmacotherapy 1990; 10 Suppl.: 134–40

    Google Scholar 

  17. Miller R, Bates JH. Amphotericin B toxicity. A follow up report of 53 patients. Ann Intern Med 1969; 71: 1090–5

    Google Scholar 

  18. Clift RA. Candidiasis in the transplant patient. Am J Med 1984; 77: 34–8

    PubMed  CAS  Google Scholar 

  19. Shulman H, Striker G, Deeg HJ, et al. Nephrotoxicity of cyclosporin A after allogeneic marrow transplantation. N Engl J Med 1981; 305: 1392–5

    Article  PubMed  CAS  Google Scholar 

  20. Coune A. Liposomes as drug delivery system in the treatment of infectious disease: potential applications and clinical experience. Infection 1988; 16: 141–7

    Article  PubMed  CAS  Google Scholar 

  21. Lopez-Berestein G, Fainstein V, Hopfer R, et al. Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. J Infect Dis 1985; 151: 704–10

    Article  PubMed  CAS  Google Scholar 

  22. Lopez-Berestein G, Bodey GP, Fainstein V, et al. Treatment of systemic fungal infections with liposomal amphotericin B. Arch Intern Med 1989; 149: 2533–6

    Article  PubMed  CAS  Google Scholar 

  23. Meunier F, Sculier JP, Coune A, et al. Amphotericin B encapsulated in liposomes administered to cancer patients. Ann N Y Acad Sci 1988; 544: 598–610

    Article  PubMed  CAS  Google Scholar 

  24. Sculier J-P, Coune A, Meunier F, et al. Pilot study of amphotericin B entrapped in sonicated liposomes in cancer patients with fungal infections. Eur J Cancer Clin Oncol 1988; 24: 527–38

    Article  PubMed  CAS  Google Scholar 

  25. Gregoriadis G. Overview of liposomes. J Antimicrob Chemother 1991; 28 Suppl. B: 39–48

    PubMed  CAS  Google Scholar 

  26. Sculier JP, Bron D, Coune A, et al. Successful treatment with liposomal amphotericin B in two patients with persisting fungemia. Eur J Clin Microbiol Infect Dis 1989; 8: 903–7

    Article  PubMed  CAS  Google Scholar 

  27. Björkholm M, Kållberg N, Grimfors G, et al. Successful treatment of hepatosplenic candidiasis with a liposomal amphotericin B preparation. J Intern Med 1991; 230: 173–7

    Article  PubMed  Google Scholar 

  28. Hay RJ. Overview of the treatment of disseminated fungal infections. J Antimicrob Chemother 1991; 28 Suppl. B: 17–25

    PubMed  Google Scholar 

  29. Butler WT, Bennet JE, Alling D, et al. Nephrotoxicity of amphotericin B: early and late effects in 81 patients. Ann Intern Med 1964; 61: 175–87

    PubMed  CAS  Google Scholar 

  30. Branch RA. Prevention of amphotericin B-induced renal impairment. A review of the use of sodium supplementation. Arch Intern Med 1988; 148: 2389–94

    Article  PubMed  CAS  Google Scholar 

  31. Bianco JA, Appelbaum FR, Nemunaitis J, et al. Phase I–II trial of pentoxiphylline for the prevention of transplant-related toxicity following bone marrow transplantation. Blood 1991; 78: 1205–11

    PubMed  CAS  Google Scholar 

  32. Milpied N, Attal M, for the SFGM (Société Francaise de Greffe de Moelle). Double blind placebo controlled trial of IV then PO pentoxifylline (PTX) in the prevention of transplant related toxicity (TRT) after allogeneic bone marrow transplantation (BMT) [abstract no. 544]. 21st Annual Meeting of the EBMT and 11th Meeting of the Nurses Group. 1995 Mar 19–23; Davos, Switzerland

    Google Scholar 

  33. Medoff G, Comfort M, Kobayashi GS. Synergistic action of amphotericin B and 5-fluorocytosine against yeast-like organisms. Proc Soc Exp Biol Med 1971; 138: 571–4

    PubMed  CAS  Google Scholar 

  34. Francis P, Walsh TJ. Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy. Clin Infect Dis 1992; 15: 1003–18

    Article  PubMed  CAS  Google Scholar 

  35. Kauffmann CA, Frame PT. Bone marrow toxicity associated with 5-fluorocytosine therapy. Antimicrob Agents Chemother 1977; 11: 244–7

    Article  Google Scholar 

  36. Janknegt R, de Marie S, Bakker-Woudenberg AJM, et al. Liposomal and lipid formulations of amphotericin B. Clin Pharmacokinet 1992; 23: 279–91

    Article  PubMed  CAS  Google Scholar 

  37. Lopez-Berestein G, Bodey GP, Frankel LS, et al. Treatment of hepatosplenic candidiasis with liposomal amphotericin B. J Clin Oncol 1987; 5: 310–7

    PubMed  CAS  Google Scholar 

  38. Gregoriadis G. Fate of injected liposomes: observations on entrapped solute retention, vesicle clearance and tissue distribution in vivo. In: Gregoriadis G, editor. Liposomes as drug carriers: recent trends and progress. Chichester: Wiley, 1988: 3–18

    Google Scholar 

  39. Anaissie E, Paetznick V, Proffitt R, et al. Comparison of the in vitro antifungal activity of free and liposome-encapsulated amphotericin B. Eur J Clin Microbiol Infect Dis 1991; 10: 665–8

    Article  PubMed  CAS  Google Scholar 

  40. Harrison LH, Stevens DA. Comparison of antifungal activity of amphotericin B deoxycholate suspension with that of amphotericin B sulfate colloidal dispersion. Antimicrob Agents Chemother 1992; 36: 486–8

    Article  Google Scholar 

  41. Clark J, Whitney RR, Olsen SJ, et al. Amphotericin B lipid complex therapy of experimental fungal infections in mice. Antimicrob Agents Chemother 1991; 35: 615–21

    Article  PubMed  CAS  Google Scholar 

  42. Juliano RL, Grant CWM, Barber KR, et al. Mechanisms of the selective toxicity of amphotericin B incorporated into liposomes. Mol Pharmacol 1987; 31: 1–11

    PubMed  CAS  Google Scholar 

  43. Ekelöf Andström E, Ringdén O, Remberger M, et al. Safety and efficacy of liposomal amphotericin B in allogeneic bone marrow transplant recipients — improvements gained. Bone Marrow Transplant. In press

  44. Meunier F, Prentice HG, Ringdén O. Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial. J Antimicrob Chemother 1991; 28 Suppl. B: 83–91

    PubMed  Google Scholar 

  45. Tollemar J, Ringdén O, Tydén G. Liposomal amphotericin-B (AmBisome) treatment in solid organ and bone marrow transplant recipients: efficacy and safety evaluation. Clin Transplant 1990; 4: 167–75

    Google Scholar 

  46. Ringdén O, Andström E, Remberger M, et al. Safety of liposomal amphotericin B (AmBisome) in 187 transplant recipients treated with cyclosporin. Bone Marrow Transplant 1994; 14 Suppl. 5: S10–S14

    PubMed  Google Scholar 

  47. Tollemar J, Andersson S, Ringdén O, et al. A retrospective clinical comparison between antifungal treatment with liposomal amphotericin B (AmBisome) and conventional amphotericin B in transplant recipients. Mycoses 1992; 35: 215–20

    Article  PubMed  CAS  Google Scholar 

  48. Tollemar J, Ringdén O, Andersson S, et al. Randomized double-blind study of liposomal amphotericin B (AmBisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant 1993; 12: 577–82

    PubMed  CAS  Google Scholar 

  49. Tollemar J, Höckerstedt K, Ericzon BG, et al. Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients. Transplantation 1995; 59: 45–50

    Article  PubMed  CAS  Google Scholar 

  50. de Marie S, Janknegt R, Bakker-Woudenberg IAJM. Clinical use of liposomal and lipid-complexed amphotericin B. J Antimicrob Chemother 1994; 33: 907–16

    Article  PubMed  Google Scholar 

  51. Smith OP, Gale R, Hamon M, et al. Amphotericin B-induced nephrogenic diabetes insipidus: resolution with its liposomal counterpart [letter]. Bone Marrow Transplant 1994; 13(1): 107–8

    PubMed  CAS  Google Scholar 

  52. Laing RBS, Milne LJR, Leen CLS, et al. Anaphylactic reactions to liposomal amphotericin [letter]. Lancet 1994; 344: 682

    Article  PubMed  CAS  Google Scholar 

  53. Aguado JM, Hidalgo M, Moya I, et al. Ventricular arrhythmias with conventional and liposomal amphotericin [letter]. Lancet 1993; 342: 1239

    Article  PubMed  CAS  Google Scholar 

  54. Sanders SW, Buchi KN, Goddard MS, et al. Single-dose pharmacokinetics and tolerance of a cholesteryl sulfate complex of amphotericin B administered to healthy volunteers. Antimicrob Agents Chemother 1991; 35: 1029–34

    Article  PubMed  CAS  Google Scholar 

  55. Goulding NM. Drug alert [letter]. MDR 22-12/94. London: Medicines Control Agency, 1994

    Google Scholar 

  56. Herbrecht R. Safety of amphotericin B colloidal dispersion (ABCD) in disseminated fungal infections. In: Mackenzie DWR, editor. Amphotericin B colloidal dispersion (ABCD) in the treatment of disseminated fungal infections. Proceedings of Round Table Seminar: 1993 Sept 30: London. London: Royal Society of Medicine Services Limited, 1993; 32: 49–56

    Google Scholar 

  57. Hostetler JS, Caldwell JW, Johnson RH, et al. Coccidiodial infections treated with amphotericin B colloidal dispersion (Amphocil or ABCD) [abstract 628]. Program and Abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology; 1992 Oct 11–14; Anaheim, 215

    Google Scholar 

  58. Bowden R, Cays M. Phase I study of amphotericin B colloidal dispersion (ABCD) for the treatment of invasive fungal infection after marrow transplant [abstract 621]. Program and Abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology; 1992 Oct 11–14; Anaheim, 215

    Google Scholar 

  59. Bowden RA, Cays M. Phase I safety study of amphotericin B colloidal dispersion (ABCD: Amphocil) for the treatment of invasive fungal infection after marrow transplant [abstract 1685]. American Society of Hematology Meeting, 1993 Dec 3–7; St. Louis. Blood 1993; 82 Suppl. 10: 425a

    Google Scholar 

  60. Wingard JR, Walker RC. Efficacy of amphotericin B lipid complex in the treatment of bone marrow transplant recipients with life-threatening systemic mycoses [poster no. 1928]. 36th Annual Meeting and Exposition of the American Society of Hematology. 1994 Dec 5; Nashville.

    Google Scholar 

  61. Anaissie EJ, Ramphai R. Efficacy and safety of amphotericin B lipid complex (ABLC) in the treatment of patients with life-threatening fusariosis [poster no. M87]. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1994 Oct 7; Orlando.

    Google Scholar 

  62. Lister J. Amphotericin B lipid complex in the management of serious systematic mycoses in patients intolerant to amphotericin B therapy [poster no. 1209]. 36th Annual Meeting and Exposition of the American Society of Hematology. 1994 Dec 5; Nashville.

    Google Scholar 

  63. Hiemenz JW, Anaissie EJ, Walsh TJ. Amphotericin B lipid complex for the treatment of severe systemic mycosis in patients with hématologic malignancies [poster no. 1207]. 36th Annual Meeting and Exposition of the American Society of Hematology. 1994 Dec 5; Nashville.

    Google Scholar 

  64. Walsh TJ, Hiemenz JW, Seibel N, et al. Amphotericin B complex in the treatment of 228 cases of invasive mycosis [poster no. M69]. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1994 Oct 7; Orlando.

    Google Scholar 

  65. Persson U, Ragnarsson Tennvall G, Andersson S, et al. Cost-effectiveness analysis of treatment with liposomal amphotericin B versus conventional amphotericin B in organ or bone marrow transplant recipients with systemic mycoses. PharmacoEconomics 1992; 2: 500–8

    Article  PubMed  CAS  Google Scholar 

  66. Ringdén O, Meunier F, Tollemar J, et al. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother 1991; 28 Suppl. B: 73–82

    PubMed  Google Scholar 

  67. Chopra R, Fielding A, Goldstone AH. Successful treatment of fungal infections in neutropenic patients with liposomal amphotericin (AmBisome) — a report on 40 cases from a single centre. Leuk Lymphoma 1992; 7: 73–7

    Article  PubMed  Google Scholar 

  68. Mills W, Chopra R, Linch DC, et al. Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-centre experience of 133 episodes in 116 patients. Br J Haematol 1994; 86: 754–60

    Article  PubMed  CAS  Google Scholar 

  69. Ringdén O, Tollemar J. Liposomal amphotericin B (AmBisome) treatment of invasive fungal infections in immunocompromised children. Mycoses 1993; 36: 187–92

    Article  PubMed  Google Scholar 

  70. Berenguer I, Munos P, Fernandez-Baca V, et al. Treatment of deep fungal infections with AmBisome [abstract no. 68]. Trends in invasive fungal infections II. 1993 Sept 2–4; Manchester, UK.

    Google Scholar 

  71. Coker RJ, Viviani M, Gazzard BG, et al. Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS. AIDS 1993; 7: 829–35

    Article  PubMed  CAS  Google Scholar 

  72. Hood J, Balfour A, Richardson M, et al. Invasive aspergillosis in cardiac transplant recipients [abstract no. 66]. Trends in invasive fungal infections II. 1993 Sept 2—4; Manchester, UK.

    Google Scholar 

  73. De Bock R, Marinus A, Nagler C, et al. EBMT/EORTC study on invasive fungal infections (IFI) in bone marrow transplant (BMT) patients [abstract no. 435]. Bone Marrow Transplant 1995; 15 Suppl. 2: S104

    Google Scholar 

  74. Viviani MA, Cofrancesco E, Boschetti E, et al. Eradication of fusarium infection in a leukopenic patient treated with liposomal amphotericin B. Mycoses 1991; 34: 255–6

    Article  PubMed  CAS  Google Scholar 

  75. Fisher EW, Toma A, Fisher PH, et al. Rhinocerebral mucormycosis: use of liposomal amphotericin B. J Laryngol Otol 1991; 105: 575–7

    Article  PubMed  CAS  Google Scholar 

  76. Davidson RN, Croft SL, Scott AG, et al. Liposomal amphotericin B in drug-resistant visceral leishmaniasis. Lancet 1991; 337: 1061–2

    Article  PubMed  CAS  Google Scholar 

  77. Tollemar J, Höckerstedt K, Ericzon BG, et al. Prophylaxis with liposomal amphotericin B (AmBisome) prevents fungal infections in liver transplant recipients: long-term results of a randomized, placebo-controlled trial. Transplant Proc 1995; 27: 1195–8

    PubMed  CAS  Google Scholar 

  78. Amphocil — amphotericin B colloidal dispersion. Technical Monograph. Zeneca Ltd., UK. 1994

  79. Oppenheim BA. Efficacy of amphotericin B colloidal dispersion (ABCD) in disseminated fungal infections (with particular reference to aspergillosis). In: Mackenzie DWR, editor. Amphotericin B colloidal dispersion (ABCD) in the treatment of disseminated fungal infections. Proceedings of Round Table Seminar: 1993 Sept 30: London. London: Royal Society of Medicine Services Limited, 1993; 32: 57–67

    Google Scholar 

  80. Bowden RA, Cays M. Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infection after marrow transplant [abstract no. 56]. Trends in Invasive Fungal Infection II; 1993 Sep 2–4; Manchester, UK

    Google Scholar 

  81. Diteze R, Falquieto A, Ksionski G, et al. Treatment of visceral leishmaniasis with Amphocil (amphotericin B cholesterol dispersion) [abstract no. 226]. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy. 1992 Oct 11–14; Anaheim.

    Google Scholar 

  82. Grunewald T, Dormann A, Rui B. Treatment failure of amphotericin B colloidal dispersion (ABCD) in AIDS-associated cryptococcal meningitis — report of two cases [abstract no. 1209]. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy. 1992 Oct 11–14; Anaheim.

    Google Scholar 

  83. Einsele H, Hebart H, Schumacher U, et al. Detection of various fungal pathogens in blood samples by PCR [abstract no. 432]. Bone Marrow Transplant 1995; 15 Suppl. 2: S103

    Google Scholar 

  84. Chryssanthou E, Andersson B, Petrini B, et al. Detection of Candida albicans DNA in serum by Polymerase chain reaction. Scand J Infect Dis 1994; 26: 479–85

    Article  PubMed  CAS  Google Scholar 

  85. Shah PM, Just KG. Fungal infections in organ transplantation. In: Holmberg K, Meyer R, editors. Diagnosis and therapy of systemic fungal infections. New York: Raven Press, 1989: 71–8

    Google Scholar 

  86. Kaplan RM, Bush JW. Health related quality of life measurement for evaluation research and policy analysis. Health Psychol 1982; 1: 61–80

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Transplantation Surgery and Clinical Immunology, Huddinge Hospital, Karolinska Institutet, S-141 86, Stockholm, Huddinge, Sweden

    Jan Tollemar & Olle Ringdén

Authors
  1. Jan Tollemar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Olle Ringdén
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tollemar, J., Ringdén, O. Lipid Formulations of Amphotericin B. Drug-Safety 13, 207–218 (1995). https://doi.org/10.2165/00002018-199513040-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199513040-00001

Keywords

Search

Navigation